[Entering Position in Introgen Therapeutics (INGN)]
Dear Member:
An awful lot looks good to me with Introgen Therapeutics (INGN). It is in a nice uptrend with a break above resistance and positive DMI . The downsides that it is a small drug company dependent primarily on a cancer drug in the pipeline and MACD is still negative. I am placing an order to buy at a limit of $5.55 for the day. Initial exit if I am wrong on direction would be on a close below the short term uptrend and a failure to jump back up the following day.
DISCLOSURE: At the time of publication, I have no position in INGN.
Sincerely,
Bill Kraft
|
